• Explore /
  • Poster
  • / Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.

Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.

Abstract Poster

Authors

Eugene Shenderov

Eugene Shenderov

Johns Hopkins University School of Medicine, Baltimore, MD

Eugene Shenderov , Angelo M De Marzo , Tamara L. Lotan , Hao Wang , Su Jin Lim , Mohamad E. Allaf , Paul A. Moore , Francine Chen , Kristina Sorg , Andrew M White , Briana Hudson , Paul A. Fields , Shaohui Hu , Samuel R. Denmeade , Kenneth J. Pienta , Christian P. Pavlovich , Charles G. Drake , Drew M. Pardoll , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT02923180

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5015)

DOI

10.1200/JCO.2022.40.16_suppl.5015

Abstract #

5015

Poster Bd #

199

Abstract Disclosures

Similar Posters

First Author: Eugene Shenderov

Poster

2024 ASCO Genitourinary Cancers Symposium

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).

First Author: Yu-Wei Chen

First Author: Jiwon Lee

First Author: Manish R. Patel